Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Late Stage

Products in Late Stage Development

Spectrum has three late-stage drug candidates including SPI-2012, a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that is being investigated for the treatment of chemotherapy-induced neutropenia in patients with breast cancer, Evomela (melphalan hydrochloride) for injection, a new IV formulation of melphalan that has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting and apaziquone, a synthetic bio-reductive agent being investigated in the treatment of non-muscle invasive bladder cancer.

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company


spectrum pharmaceuticals products